for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biohaven Pharma says acute migraine treatment succeeds in study

Dec 17 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd said on Tuesday two doses of its experimental treatment for acute migraine were effective in reducing headaches in a large study.

The drug, vazegepant, belongs to a new class of treatments for migraine called CGRP inhibitors. (Reporting by Manojna Maddipatla in Bengaluru Editing by Saumyadeb Chakrabarty)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up